OncoGenex Pharma (OGXI) Misses Q2 EPS by 1c

OncoGenex Pharma (NASDAQ: OGXI) reported Q2 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $1.17 million.

As of June 30, 2016, the company's cash, cash equivalents, and short-term investments were $39.7 million compared with $55.2 million as of December 31, 2015.

For earnings history and earnings-related data on OncoGenex Pharma (OGXI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Jack Henry (JKHY) Tops Q4 EPS by 13c